Aspirin, not without bleeding risk in the real world: results of a UK cohort study evaluating the use of antiplatelet therapy for stroke prevention in atrial fibrillation (AF)
Bristol-Myers Squibb Pharmaceuticals Limited , London (United Kingdom of Great Britain & Northern Ireland)
0
follower
24
more
presentations
in this session
Patients with atrial fibrillation treated with apixaban are less likely to discontinue study drug when compared with warfarin: insights from the ARISTOTLE trial
Incidence of intracranial hemorrhage in the years 2013-15 in patients with atrial fibrillation in anticoagulant therapy: preliminary analysis of data from Ravenna registers
CHA2DS2-Vasc score, as well as age and body mass index as the main risk factors of brain lesions in asymptomatic patients with paroxysmal non-valvular atrial fibrillation